At the time of writing, Standard BioTools Inc [LAB] stock is trading at $1.40, down -0.71%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LAB shares have gain 6.87% over the last week, with a monthly amount drifted -19.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Standard BioTools Inc [NASDAQ: LAB] stock has seen the most recent analyst activity on April 16, 2024, when TD Cowen initiated its Buy rating and assigned the stock a price target of $3.50. Previously, Jefferies started tracking the stock with Buy rating on April 04, 2024, and set its price target to $3.25. On July 12, 2023, KeyBanc Capital Markets initiated with a Overweight rating and assigned a price target of $4 on the stock.
For the past year, the stock price of Standard BioTools Inc fluctuated between $1.17 and $3.04. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Standard BioTools Inc [NASDAQ: LAB] shares were valued at $1.40 at the most recent close of the market. An investor can expect a potential return of 132.14% based on the average LAB price forecast.
Analyzing the LAB fundamentals
According to Standard BioTools Inc [NASDAQ:LAB], the company’s sales were 155.90M for trailing twelve months, which represents an 77.27% jump. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -0.82%, Pretax Profit Margin comes in at -0.8%, and Net Profit Margin reading is -0.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.29 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3433 points at the first support level, and at 1.2867 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4833, and for the 2nd resistance point, it is at 1.5667.
Ratios To Look Out For
It is important to note that Standard BioTools Inc [NASDAQ:LAB] has a current ratio of 3.76. As well, the Quick Ratio is 3.41, while the Cash Ratio is 1.75. Considering the valuation of this stock, the price to sales ratio is 3.34, the price to book ratio is 1.07.
Transactions by insiders
Recent insider trading involved Black Jeffrey G., Former Officer, that happened on Nov 12 ’24 when 57971.0 shares were purchased. Former Officer, Taich Adam completed a deal on Sep 09 ’24 to buy 45851.0 shares. Meanwhile, Director Casdin Partners Master Fund, L bought 0.25 million shares on Aug 27 ’24.
